Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,1477610,peak plasma cyclopentolate concentrations,"There was a marked interindividual variation in peak plasma cyclopentolate concentrations ranging from undetectably low to 5.8 ng/ml (median, 2.9 ng/ml).",Systemic absorption of ocular cyclopentolate in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1477610/),[ng] / [ml],5.8,89126,DB00979,Cyclopentolate
,1477610,peak plasma cyclopentolate concentrations,"There was a marked interindividual variation in peak plasma cyclopentolate concentrations ranging from undetectably low to 5.8 ng/ml (median, 2.9 ng/ml).",Systemic absorption of ocular cyclopentolate in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1477610/),[ng] / [ml],2.9,89127,DB00979,Cyclopentolate
,9527641,peak plasma concentration,"In healthy volunteers peak plasma concentration of cyclopentolate, 2.06+/-0.86 (mean+/-S.D.) nM, occurred at 53 min., maximum receptor occupancy being 5.9+/-2.1%.",Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527641/),nM,2.06,236803,DB00979,Cyclopentolate
,9527641,maximum receptor occupancy,"In healthy volunteers peak plasma concentration of cyclopentolate, 2.06+/-0.86 (mean+/-S.D.) nM, occurred at 53 min., maximum receptor occupancy being 5.9+/-2.1%.",Systemic and ocular absorption and antagonist activity of topically applied cyclopentolate in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9527641/),%,5.9,236804,DB00979,Cyclopentolate
,8512760,Peak plasma drug concentrations,2. Peak plasma drug concentrations of about 3 ng ml-1 occurred within 30 min after all formulations.,Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512760/),[ng] / [ml],3,256891,DB00979,Cyclopentolate
,8512760,elimination half-life,The mean elimination half-life of cyclopentolate was 111 min when all subjects and formulations were considered together.,Plasma concentrations and ocular effects of cyclopentolate after ocular application of three formulations. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8512760/),min,111,256892,DB00979,Cyclopentolate
